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Breast cancer is one of the most common maliglnancies affecting women worldwide. Despite the fact that early disease can be cured by surgery, at 
least 30% of patients develop disease recurrence, while 
only 40% of patients with nodelpositive disease are alive 
without disease recurrence at 10 years.1 Prognostic facl
tors, which include growth factors and oncogenes, not 
only help in assessing the overall prognosis, but also 
serve a crucial role in the treatment decision. Two of 
the most studied prognostic factors are hormone recepl
tors (HR) and amplification of the human epidermal 
growth factor receptor 2 (HER2) oncogene. The latter 
is present in approximately 20% of cases, almost half of 
which also express HR. These factors are also predictive 
of response to systemic treatments, including targeted 
agents. Thus, in addition to the demonstrated benefit 
of adjuvant hormonal therapy, some recent randomized 
trials have shown a clinical benefit of adding trastuzuml
ab, a humanized monoclonal antibody directed against 
the extracellular domain of HER2, to chemotherapy in 
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BACKGROUND: this study was conducted to determine the prognostic effect hormone receptor (hr) status in 
early her2 positive (her2+) breast cancer patients, since it has not yet been established whether hr status can 
be used in the prognosis of patients with (her2+) breast cancer.
PATIENTS AND METHODS: We obtained data from 299 patients with early her2+ breast cancer who under-
went surgery and received standard adjuvant chemotherapy, hormonal therapy and/or radiation between 2000 
and 2002 at the instituto nacional de enfermedades neoplasicas, perú. clinical and pathological features were 
compared. endpoints analyzed were disease free survival (dfs) and overall survival (os).
RESULTS: overall, 155 patients were hr-positive (hr+) and 144 were negative (hr-). the two groups had 
similar characteristics except for histologic grade and extracapsular extension. With a median follow-up of 93 
months, 5-year dfs was statistically different between the two groups: 65.0% for (her2+/ hr-) and 74.6% for 
the (her2+/ hr+) patients (p=.045). os at 5 years was not statistically different between the two groups with 
75.5% for (her2+/ hr-) patients and 82.4% for the (her2+/ hr+)(p=.140).
CONCLUSIONS: patients with (her2+/ hr-) breast cancers treated with surgery and standard adjuvant chemo-
therapy exhibited a statistically worse dfs compared to those with (her2+/ hr+) tumors. however, os was 
similar in both groups.
early breast cancer patients.2l5
Hormone and HER2 receptor pathways are intil
mately related and a complex network between them 
has been demonstrated. A variety of in vitro and in 
vivo models have shown an inverse relationship bel
tween HER2 overexpression and rates and duration of 
response to hormone modulation.6l8 Additionally, an 
inverse relationship between positive staining for the 
estrogen receptor and HER2 overexpression has been 
described.5,9 Clinical evidence of the participation of the 
HER2 pathway in endocrine resistance in the adjuvant 
breast cancer setting, is prognostically detrimental in 
patients with positive steroid receptor who overexpress 
HER2.5,7,8 The clinical effect of the interaction of these 
factors in the prognosis of early breast cancer is not 
completely understood. It has not yet been established 
whether hormone receptor status can be used in the 
prognosis of patients with HER2 positive (HER2+) 
breast cancer who have received standard adjuvant chel
motherapy without trastuzumab, nor if the influence 
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of HER2 in the sensitivity to hormonal therapy could 
change the treatment decision for some subsets of low 
risk breast cancer.10,11 The aim of the present study was 
to evaluate the prognostic contribution of HR status in 
relation to HER2 overexpression in breast cancer.
PATIENTS AND METHODS
We retrospectively analysed data from female patients 
with early (stage Il III) HER2+ breast cancer who unl
derwent curative surgery followed by adjuvant treatment 
at the Instituto Nacional de Enfermedades Neoplásicas 
(INEN), Lima, Peru, between 2000 and 2002. Patients 
also had to have complete clinical followlup reported in 
their medical file and detailed pathology reports.
Accepted adjuvant treatments were chemotherapy, 
endocrine treatment and local radiation, all of which 
had to have been administered according to internal
tional guidelines and or local guidelines. No patients 
had received adjuvant trastuzumab, as at the time it 
was not a standard treatment choice. Followlup after 
completion of adjuvant treatment usually involved a 
regular schedule of visits every 4 weeks initially, which 
was progressively extended to every 6 months, except 
for patients requiring more frequent visits. Patients had 
regular blood tests and image tests.
HER2 status was identified using currently applil
cable clinical methodology. The antibody antilHER2/
neu (A0485 Dako) was used to quantify immunohisl
tochemical staining. All 3+ (high intensity) staining 
specimens were considered positive. All 2+ (moderate 
intensity) staining specimens underwent florescence 
in situ hybridization (FISH) analysis, and those that 
showed HER2 amplification were classified as positive. 
Estrogen and progesterone receptors (ER and PR) 
were evaluated by immunohistochemisty, and were 
considered positive if more than 10% of tumor cells 
were positively (weak or strong) stained. 
Quantitative and qualitative variables were evalul
ated using mean and standard deviation, and proporl
tions, respectively. Differences between the two horl
mone receptor subgroups ([HER2+/ HR–] versus 
[HER2+/ HR+]) were examined using analysis of 
variance (ANOVA) for age and tumor size, with a prel
vious evaluation of the fulfilling of all, the assumption of 
normality, homogeneity of variance and independence.
The chilsquare test was used to evaluate the association 
between the different breast cancer subgroups and the 
principal clinical and pathological features of prognosl
tic importance.
Disease free survival (DFS) was chosen as the pril
mary end point and defined as the time from the primal
ry surgery to the first recurrence, death or last followl
up in the case of patients without recurrence. Overall 
survival (OS) was calculated from the time of diagnosis 
to death or last followlup. The survival curves were call
culated using the KaplanlMeier method.12
The loglrank test was used to determine the statistil
cal significance of the differences observed between the 
groups of hormone receptors ([HER2+/ HR–] versus 
[HER2+/ HR+]). Multivariate Cox regression modl
els were developed to obtain both relative risks (hazard 
ratio) and 95% confidence intervals (CIs) for the main 
clinical pathologic variables. The covariables included in 
this model were specific for age ranges, clinical stages, 
histological grade, menopausal status, vascular inval
sion, extracapsular extension and multifocallity/multil
centricity. A P value of <.05 was considered statistically 
significant. The statistical analysis was performed using 
SPSS version 15.0 (SPSS Inc., Chicago IL).
RESULTS 
Data for this retrospective analysis were obtained from 
299 patients with operable HER2 breast cancer. Patient 
demographics and disease characteristics are described 
in Table 1. The mean age was 49.4 years. Overall, 155 
patients were HR positive (51.8%), 122 (44.4%) had 
poorly differentiated tumors and 155 (51.8%) had vascul
lar invasion. Involvement of lymph nodes was observed 
in 158 (52.8%) cases. Most patients underwent radical 
mastectomy (94.6%). Complementing this, the majority 
of the patients (76.9%) received adjuvant chemotherapy, 
but this included taxanes (not concurrently with anthral
cyclines) in only a small subgroup (3.0%) because taxanes 
were initially restricted to patients with more than three 
compromised lymph nodes. Almost all patients who rel
ceived adjuvant endocrine therapy were HR+. Adjuvant 
treatment included radiation in 24.7% of patients mostly 
for axillary lymph node involvement and locally advanced 
stage. A reduced number of patients (7.4%) did not rel
ceive any adjuvant treatment, mostly due to a high risk of 
complications after individualized analysis.
Most of the well or moderately differentiated tumors 
were HR+ (61.4%) and most poorly differentiated tul
mors were HR– (50.4%). Additionally, extracapsular 
extension was more frequent (20.1%) in HR– patients. 
Aside from these differences, patient characteristics 
were comparable between the two groups in age, menol
pausal status, histological types, pTNM (stage IlIIlIII) 
status, type of initial therapy and use of adjuvant chel
motherapy and radiation (Table 1). The most frequent 
recurrence locations were bone, lung, liver, and ipsilatl
eral supraclavicular lymph nodes. In general, all recurl
rence locations except bone were more frequent in the 
HR– group (Table 2).
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Table 1. Comparison of demographics, disease characteristics and treatment by hormone receptor status in early HER2 positive breast 
cancer patients.
Variable All casesn=299
[HER2+, ER+ or PR+]
n=155 (51.8%)
[HER2+ ER- and PR-]
n=144 (48.2%) P
Patient and disease characteristics
   Mean age ± SD (years) 49.4±11.0 49.5±11.0 49.3±11.0 .881
   Premenopausal status n (%) 162 (54.2%) 87 (56.1%) 75 (52.1%) .483
   Mean tumor size ± SD (cm) 3.3±1.8 3.2±1.5 3.5±2.0 .106
   Estrogen receptor positive 146 (48.8%) 146 (94.2%) 0 (0.0%) <.0001
   Progesterone receptor positive 114 (38.1%) 114 (73.5%) 0 (0.0%) <.0001
T-status, n (%)
   T1 71 (24.1%) 41 (26.8%) 30 (21.3%)
.530
   T2 185 (62.9%) 95 (62.1%) 90 (63.8%)
   T3 27 (9.2%) 13 (8.5%) 14 (9.9%)
   T4 11 (3.7%) 4 (2.6%) 7 (5.0%)
   Tx 5 2 3
   Lymph node compromise 158 (52.8%) 87 (56.1%) 71 (49.3%) .238
AJCC stage, n (%)
   Stage I 47 (15.7%) 30 (19.4%) 17 (11.8%)
.128   Stage II 160 (53.5%) 83 (53.5%) 77 (53.5%)
   Stage III 92 (30.8%) 42 (27.1%) 50 (34.7%)
Histologic grade (Elston/Ellis), n (%)
    Well differentiated 13 (4.7%) 10 (7.1%) 3 (2.2%)
.043
   Moderately differentiated 140 (50.9%) 76 (54.3%) 64 (47.4%)
   Poorly differentiated 122 (44.4%) 54 (38.6%) 68 (50.4%)
   Unknown 24 15 9
   Vascular invasion 155 (51.8%) 82 (52.3%) 74 (51.4%) .881
   Extracapsular extension 44 (14.7%) 15 (9.7%) 29 (20.1%) .011
   Multifocality/multicentricity 31 (10.4%) 20 (12.9%) 11 (7.6%) .136
Breast surgery, n (%)
   Mastectomy 283 (94.6%) 146 (94.2%) 137 (95.1%)
.717
   Conservation 16 (5.4%) 9 (5.8%) 7 (4.9%)
Adjuvant treatment, n (%)
   Chemotherapy 230 (76.9%) 113 (72.9%) 117 (81.3%) .087
   Taxane-containing 7 (3.0%) 5 (4.4%) 2 (1.7%) .274
   Radiation 74 (24.7%) 30 (19.4%) 44 (30.6%) .025
   Hormonal therapy 157 (52.5%) 135 (87.1%) 22 (15.3%) <.0001
   Tamoxifen 107 (68.2%) 88 (65.2%) 19 (86.4%)
NA   Aromatase inhibitor 45 (28.6%) 42 (31.1%) 3 (13.6%)
   Unknowna 5 (3.2%) 5 (3.7%) 0 (0.0%)
   No adjuvant treatment 22 (7.4%) 4 (2.6%) 18 (12.5%) .001
aStudy BiG1-98, ER: estrogen receptor, PR: progesterone receptor, NA: not applicable
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Table 2. Observed first recurrences by hormone receptor status in early HER2 positive breast cancer patients.
Recurrence location All cases [Her2+, ER+ or PR+] [Her2+, ER- and PR-]
Number of 
patients
(n=90)
%
Number of 
patients 
(n=41)
%
Number of 
patients 
(n=49)
% Pa
Distant
   Bone 25 27.8% 14 34.1% 11 22.4% 0.217
   Lung nodules 22 24.4% 8 19.5% 14 28.6% 0.319
   Liver 17 18.9% 7 17.1% 10 20.4% 0.687
   Central nervous system 8 8.9% 3 7.3% 5 10.2% 0.723
   Subcutaneous and skin 11 12.2% 3 7.3% 8 16.3% 0.194
   Contralateral breast 4 4.4% 2 4.9% 2 4.1% 0.999
   Other places 18 20.0% 7 17.1% 11 22.4% 0.525
Locoregional
   Ipsilateral supraclavicular 
   lymph nodes 16 17.8% 6 14.6% 10 20.4% 0.476
   Mastectomy scar 10 11.1% 4 9.8% 6 12.2% 0.750
   Ipsilateral axillary lymph 
   nodes 2 2.2% 1 2.4% 1 2.0% NA
aChi-square test or exact test of Fisher, ER: estrogen receptor, PR: progesterone receptor, NA: not applicable
The median followlup time for the total 299 patients 
was 93 months (range 12l115 months). During this pel
riod of observation, 90 (31.1%) patients developed disl
ease recurrence at a local, regional or distal level and 55 
(18.4%) deaths were registered.
In the complete data set, the mean DFS and OS 
were 4.24 and 4.60 years, respectively. Median for 
both parameters had not been reached at the time of 
analysis. 
Steroid receptor status and survival
Analysis according to HR status revealed that the rel
currence curve for the HER2+/ HR− group was all
ways higher than for the HER2+/ HR+ group, the 
peak of recurrences for both groups being found durl
ing the second and third years after surgery; recurrencl
es were rare after the fourth year (Figure 1). The disl
tribution of the curves showed that recurrences in the 
HER2+/ HR− group were more frequent during the 
second year; this was followed by a steep fall, while the 
recurrences in the HER2+/ HR+ group were more 
constant during the four years.
In loglrank testing, HER2+/ HR− patients were 
significantly more likely to relapse than HER2+/ HR+ 
patients, giving 5lyear breast cancer free survival rates 
of 65.0% and 74.6% (P=.045, Figure 2) and mean DFS 
of 3.97 and 4.38 years, respectively. Medians were not 
reached, but DFS rates were 71.4% and 65.0% at 3 and 
5 years, respectively for HER2+/ HR− patients. Also 
DFS rates for HER2+/ HR+ patients were 83.1% and 
74.6% at 3 and 5 years, respectively.
In the multivariate Cox regression analysis, the 
only covariable with a significant effect on the time 
to recurrence (besides the absence of HR, P=.022), 
was pathological compromise of axillary lymph nodes 
(P<.001). As such, the absence of HRs increased the 
recurrence risk by more than 1.7lfold over the presence 
of HRs (hazard ratio= 1.707, 95% CI; 1.079l2.699). 
Furthermore, N3 pathologic compromise increased the 
risk of recurrence by twolfold (hazard ratio=5.423, 95% 
CI; 2.823l10.418). Statistically significant differences 
were not reported in 5lyear OS between the populal
tions, being 75.5% and 82.4% for HER2+/ HR− and 
HER2+/ HR+ tumors (P=.140), respectively. Mean 
OS was 4.5 and 4.7 years for the absence and presence 
of HR, respectively (Figure 3).
DISCUSSION
Breast cancer is a heterogeneous disease. Despite the 
fact that data for hormone receptor and HER2 status 
are not as exact as genetic analyses, it is clear that recepl
tor status information is much more readily available 
and can give us an extremely useful tool for obtaining inl
formation about the behavior of the disease in patients 
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in a clinic setting.13,14 We evaluated a homogeneous set 
of patients with early breast cancer who had overexpresl
sion of HER2, and compared survival in the presence or 
absence of steroid receptors. With expression of at least 
one of the steroid receptors (estrogen or progesterone), 
a treatment decision was made (although controversial), 
based on the fact that the progesterone receptor gene is 
regulated by the estrogen pathway and the observation 
of a response to endocrine therapy is achieved in the 
expression of either receptor. 
Our results show that for the overall HER2+ pal
tient population, the HR− group has a higher rate of 
aggressive features such as poor differentiation and 
extracapsular extension than in the HR+ population. 
Furthermore, the absence of HR is associated with a 
higher risk of relapse at 5 years and a tendency towards 
earlier recurrences. Bone metastasis as the first location 
of recurrence was more common in the HR+ populal
tion. These results correlate with the findings of other 
studies, including the Carolina Breast Cancer Study 
which suggests a shorter DFS for HER+/ HR− verl
sus HER+/ HR+ status for 5lyear survival, with rates 
of 52% and 87%, respectively.15 In addition, the HERA 
trial, which evaluated 1698 HER2+ early breast cancer 
patients in the nonltrastuzumab (observational) arms, 
found a DFS at 3 years of 70% and 78% for the absence 
and presence of hormone receptor, respectively.16 These 
and other studies also show differences in the pattern 
of relapses between the populations, with a very high 
risk of early recurrence for the absence of hormone rel
ceptor, but a consistently high risk over time for the 
presence of hormone receptor. Theses data are also in 
agreement with the association between the presence of 
bone metastases and HR positivity.15l17 Response and 
recurrence patterns represents the interaction of several 
variables instead of the single poor prognosis−factors 
represented by the combination of HER2 overexpresl
sion and lack of hormonal receptors; for example, only 
HR patients benefit from adjuvant hormonal therapy, 
but the benefits for adjuvant chemotherapy are not 
great as compared with those for patients with ERl
negative disease;18 but in the subset of node positive 
HER2+ patients, ERlnegative and ERlpositive have a 
similar benefit from standard chemotherapy.19
Preclinical and clinical experience has demonstrated 
an additive effect when combining hormonal therapy 
and therapy targeted to HER2.20l22 The HERA trial 
results show that trastuzumab has an additive effect 
to adjuvant hormonal therapy, producing a benefit 
that is independent of hormone status (increase in 3l
year DFS of 6.1% and 6.6% for hormone receptor stal
tus negative and positive, respectively). However, the 
pattern of treatment benefits over the recurrence risk 
may differ with followlup, with a predominant activity 
preventing early recurrences in HR− and producing a 
sustained reduction in HR+ tumors.16 Another point 
is the evidence that in patients overexpressing HER2, 
trastuzumab achieved a modest benefit in HR positive 
patients compared with HR negative patients, although 
this difference was not statistically significant.16, 23
In summary, we observed significant differences in 
histologic grade and extracapsular invasion in HR− 
and HR+ groups. This difference in pathologic charl
acteristics could lead to a bias in our analysis of the 
impact of HR, but in a previous work in 1198 patients 
in our population we observed this difference, which 
could be explained by the tumor biology instead of 
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sampling bias.24  Our results suggest that in the early 
breast cancer patients with overexpression of HER2, 
the absence of hormone receptors is significantly asl
sociated with a more aggressive behavior and a poor 
prognosis. Despite of clinical evidence showing the 
benefit of adding trastuzumab to adjuvant treatment, 
the prognosis is slightly worse with positive hormonal 
receptor tumors. 
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